Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 601–700 of 999
Unravelling the Effect of Sacubitril/Valsartan on Loop Diuretic Dosing
ter Maaten, J. M. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1410 · Cited by 7
Davogustto, G., Wells, Q. S., Harrell, F. E., Greene, S. J., Roden, D. M., & Stevenson, L. W. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.02.003 · Cited by 8
Nguyen, D. V., Pham, G. T., Pham, S. N., & Nguyen, H. T. T. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000003972 · Cited by 8
Sze, S., Thaitirarot, C., Krishnan, S., Chan, D., Nicolson, W., Squire, I. B., Clayton, L., & Loke, I. W. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100296 · Cited by 6
Williams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000140 · Cited by 12
Rahil, A., Bhavsar, T., Fatima, R., Rajkumar, A., Kumar, J., Majidan, H. A., Gajjala, N., LEFRANC, W., Deeksha, F., Lingegowda, H., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1543153 · Cited by 16
Miró, Ò., Chioncel, O. D., Mebazaa, A., Sato, N., Butler, J., Davison, B. A., Biegus, J., Pagnesi, M., Ambrosy, A. P., Savarese, G., et al. (2025) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000001270 · Cited by 10
Self-citationLiu, L., Ding, X., Han, Y., & Lv, J. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/7840852 · Cited by 6
RetractedHaseeb, M. T., Aslam, M. N., Avanteeka, F., Khalid, U. A. R., Ahmad, D. Z., Senaratne, M., Almaalouli, B., & Hirani, S. (2023) · Cureus · doi:10.7759/cureus.36392 · Cited by 7
Roca, L. N., Cortés, M., Germán, J. B., Becerra, A. J. B., Otero, J. M. R., Chapel, J. A. E., López, C. R., Lázaro, A. M. P., Urquía, M. T., & Tuñón, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164772 · Cited by 6
Pietro, G. D., Improta, R., Severino, P., D’Amato, A., Birtolo, L. I., FILIPPO, O. D., Lattanzio, A., Cristofaro, R. D., Galardo, G., D'Ascenzo, F., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15082 · Cited by 7
Novel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure
Lima, I. G. C. V., Nunes, J. T., Godoy, L. C., McDonald, M., & Bocchi, E. A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101451 · Cited by 11
In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors—The Time Is Now
Srivastava, P. K., & Fonarow, G. C. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0104 · Cited by 6
Tolerability and efficacy of sacubitril/valsartan in clinical practice
Nandal, S., Chow, C., Hannah, V., Vaddadi, G., & van Gaal, W. (2020) · Internal Medicine Journal · doi:10.1111/imj.14749 · Cited by 7
Heart Failure Trial Update—Analysis of Recent Data
Mohananey, D., Mewhort, H. E., Shekhar, S., Mohananey, A., Chaudhary, R., Gaglianello, N. A., & Ramakrishna, H. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.09.085 · Cited by 6
Riaz, M., Smith, S. M., Dietrich, E. A., Pepine, C. J., & Park, H. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2610 · Cited by 8
Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity
Dankowski, R., Sacharczuk, W., Łojko‐Dankowska, A., Nowicka, A., Szałek-Goralewska, A., & Szyszka, A. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0052 · Cited by 6
Kawamoto, Y., Nishihara, T., Aono, J., Nandate, H., Hamada, T., Yasuoka, T., Matsumoto, T., Yamaguchi, O., Sugiyama, T., & Yorozuya, T. (2021) · Journal of International Medical Research · doi:10.1177/03000605211063077 · Cited by 6
‘Acute Heart Failure’: Should We Abandon the Term Altogether?
Straw, S., Napp, A., & Witte, K. K. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00576-9 · Cited by 6
Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure
Greenberg, B. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000060 · Cited by 6
Sudden cardiac death prevention in the era of novel heart failure medications
Koev, I., Yarkoni, M., Luria, D. M., Amir, O., & Biton, Y. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100281 · Cited by 7
The Rare Condition of Left Ventricular Non-Compaction and Reverse Remodeling
Bustea, C., Bungău, A. F., Ţiţ, D. M., Iovanovici, D. C., Toma, M. M., BUNGAU, S. G., Radu, A.-F., Behl, T., Coțe, A., & Babeş, E. E. (2023) · Life · doi:10.3390/life13061318 · Cited by 7
Malmborg, M. W., Al-Kahwa, A., Køber, L., Torp-Pedersen, C. T., Butt, J. H., Zahir, D., Tuxen, C., Poulsen, M. K., Madelaire, C., Fosbøl, E. L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286307 · Cited by 6
Николаевна, К. О., Baranov, A. V., Sazhina, A. S., & Bogomolov, A. N. (2023) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202326051102 · Cited by 6
Sen, S. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89415 · Cited by 6
Heart Failure Without a Reduced Ejection Fraction
Kumar, S., & Psotka, M. A. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89417 · Cited by 6
Morbach, C., Simon, I., Danner, E., Gelbrich, G., Stefenelli, U., Sahiti, F., Scholz, N., Cejka, V., Albert, J., Ertl, G., et al. (2023) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyad020 · Cited by 9
Kapłon‐Cieślicka, A., Vardas, P. E., Grabowski, M., & Lelonek, M. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97062 · Cited by 9
Amin, K. D., Bethel, G., Jackson, L. R., Essien, U. R., & Sloan, C. E. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01180-5 · Cited by 5
Devadoss, R., Dhillon, G. S., Sharma, P., Verma, R. K., Munjal, R. S., & Kashyap, R. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11010015 · Cited by 10
Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure
Doherty, D. J., Docherty, K. F., & Gardner, R. S. (2024) · Heart · doi:10.1136/heartjnl-2022-322164 · Cited by 8
The neuroprotective effect of LCZ696 on methamphetamine-induced cognitive impairment in mice
Qian, L., Ruan, Y., Gong, X., Yu, Z., Lin, S., Li, X., Shen, Y., Luo, H., Si, Z., & Liu, Y. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137630 · Cited by 6
Serrano, J. A. M., Cigarroa-López, J. A., Mendoza, A. C., Ivey-Miranda, J. B., Zavala, G. H. M., Domínguez, L. O., Leal, S., Pombo-Bartelt, J. E., Garza, E. H. H., Leal, G. M., et al. (2024) · Drugs in Context · doi:10.7573/dic.2023-8-1 · Cited by 12
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications
Chow, C., Mentz, R. J., & Greene, S. J. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00512-3 · Cited by 6
Posicionamiento SEMERGEN en el abordaje de la insuficiencia cardíaca crónica en atención primaria
Moraga, M. J. C., Turégano-Yedro, M., Pallarés‐Carratalá, V., Seoane-Vicente, M. C., Cumplido, A. S., Ruiz‐García, A., Martin-Rioobó, E., Escobar-Cervantes, C., García, J. P., & Barrios, V. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.10.007 · Cited by 11
Mohebi, R., Liu, Y., Felker, G. M., PRESCOTT, M. F., Ward, J. H., Piña, I. L., Butler, J., Solomon, S. D., & Januzzi, J. L. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.08.006 · Cited by 9
Parlati, A. L. M., Basile, C., & Filardi, P. P. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad026 · Cited by 7
Acute Decompensated Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
Fukata, M. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.12.007 · Cited by 6
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients
Hwang, H. S., Kim, J. S., Kim, Y., Lee, Y. H., Lee, D.-Y., Ahn, S. Y., Moon, J.-Y., Lee, S.-H., Ko, G.-J., & Jeong, K. H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.684297 · Cited by 8
Vasodilator Therapy in Acute Heart Failure
Curfman, G. (2019) · JAMA · doi:10.1001/jama.2019.20285 · Cited by 6
Appenzeller, F., Harm, T., Sigle, M., Aidery, P., Kreißelmeier, K., Baas, L., Goldschmied, A., Gawaz, M., & Müller, K. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15100 · Cited by 5
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Park, J., Park, C. S., Rhee, T., Choi, H., Choi, H., Lee, H., Park, J., Yoon, Y. E., Lee, S., Kim, Y.-J., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328971 · Cited by 7
Jung, M., Lee, S. Y., Cho, Y. H., Bae, D., Lee, S., Lee, C. J., Son, J., Cho, J. Y., & Kim, E. J. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0037 · Cited by 5
Management of patients with heart failure and chronic kidney disease
Wu, L., Rodríguez, M., Hachem, K. E., Tang, W. H. W., & Krittanawong, C. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10415-9 · Cited by 6
Barboza, J. J., León‐Figueroa, D. A., Pasupuleti, V., Piscoya, A., Roman, Y. M., Valenzuela-Rodríguez, G., Diaz‐Arocutipa, C., & Hernández, A. V. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.01.004 · Cited by 5
Tang, S., Li, L., Chen, H., Aa, G., Liu, H., Jiang, S., Yang, Q., Yang, Q., Sun, P., Zhou, X., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133543 · Cited by 6
Bonaventura, A., Wohlford, G. F., Vecchié, A., Tassel, B. W. V., & Abbate, A. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000685 · Cited by 5
Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
Akbar, S., Kabra, N., & Aronow, W. S. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s224772 · Cited by 6
Seferovic, P. M., Polovina, M. M., Milinković, I., Anker, S. D., Rosano, G. M. C., & Coats, A. J. S. (2021) · International Journal of Heart Failure · doi:10.36628/ijhf.2021.0013 · Cited by 5
Dębska-Kozłowska, A., Książczyk, M., & Lelonek, M. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.01.003 · Cited by 6
Sex and Gender-Related Issues in Heart Failure
Romiti, G. F., Recchia, F., Zito, A., Visioli, G., Basili, S., & Raparelli, V. (2022) · Cardiology Clinics · doi:10.1016/j.ccl.2021.12.013 · Cited by 7
Adams, J., & Mosler, C. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2098118 · Cited by 6
Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists
Pipilas, A. R., Martyn, T., & Lindenfeld, J. M. (2022) · Structural Heart · doi:10.1016/j.shj.2022.100082 · Cited by 6
Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction
Krittanawong, C., Rodriguez, M., Lui, M., Misra, A., Tang, W. H. W., Bozkurt, B., & Yancy, C. W. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.01.024 · Cited by 6
Fernández, A. E., Mayoral, A. R., Franco, Á. G., Villota, J. N., Mirabet, S., Gracia, J. R., González‐Costello, J., Palomas, J. L. B., & Escobar, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2195540 · Cited by 5
Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide
Khan, M. J., Graham, F. J., Masini, G., Iaconelli, A., Friday, J. M., Lang, C. C., & Pellicori, P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01865-y · Cited by 5
Petrie, M. C., Rouleau, J. L., Claggett, B. L., Jering, K., van der Meer, P., Køber, L., Miao, Z. M., Lewis, E. F., Granger, C. B., Pasquale, C. G. D., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066163 · Cited by 5
Rahman, M. M., Rahman, A., & Nishiyama, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1451450 · Cited by 7
Dupuis, M., Raymackers, J., Ackermans, N., Boulanger, S., & Verellen‐Dumoulin, C. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01275-9 · Cited by 5
Merlo, M., Masè, M., Cannata, A. N., Zaffalon, D., Lardieri, G., Limongelli, G., Imazio, M., Canepa, M., Castelletti, S., Bauce, B., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001050 · Cited by 5
Almazroa, L., Mihajlovic, V., Lawler, P. R., & Luk, A. C. (2020) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa233 · Cited by 5
Gokhroo, R. K., Kaul, A., Tarik, M., Kailash, C. A., Rajesh, N., Ashish, K., Manish, G., & Subhash, C. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.01.010 · Cited by 6
Acute heart failure treatment: a light at the end of the tunnel?
Cotter, G., Davison, B. A., Edwards, C., Takagi, K., Solal, A. C., & Mebazaa, A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2116 · Cited by 6
Abós, C. M., Mojón, D., Rivas‐Lasarte, M., Tornero, L. C. B., Pàmies, J., Solé‐González, E., Fluvià-Brugués, P., Zegrí‐Reiriz, I., López, L., Brossa, V., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.642117 · Cited by 5
He, Y., Lu, X., Zheng, Y. W., Song, M., Shen, B., Nienaber, C. A., Chen, G., Wu, F., Zheng, J., Zhang, W., et al. (2021) · Cardiology · doi:10.1159/000512418 · Cited by 5
2021 ACC update of the heart failure guidelines
Špinar, J., Málek, F., Špinarová, L., Vítovec, J., Táborský, M., & Linhart, A. (2021) · Cor et Vasa · doi:10.33678/cor.2021.033 · Cited by 6
Disease-modifier Drugs in Patients with Advanced Heart Failure
Iacoviello, M., Vitale, E., Corbo, M. D., Correale, M., & Brunetti, N. D. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.002 · Cited by 5
Hong, J. A., Lee, S. E., Kim, S., Kim, M., Lee, H.-Y., Cho, H., Choi, J., Jeon, E., Hwang, K., Chae, S. C., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13765 · Cited by 5
Liuzzo, G., & Volpe, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab861 · Cited by 5
Zhao, X. F., Gu, B., Li, Q., Li, J., Zeng, W., Li, Y., Guan, Y., Huang, M., Lei, L., & Zhong, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.962992 · Cited by 8
Ghazi, L., O’Connor, K. D., Yamamoto, Y., Fuery, M. A., Sen, S., Samsky, M. D., Riello, R. J., Huang, J., Olufade, T. O., MCDERMOTT, J. J., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.12.002 · Cited by 5
Self-citationLitwin, S. E., & East, C. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1058998 · Cited by 5
Sakhamuri, N., Athiyaman, S., Randhi, B., Gutlapalli, S. D., Pu, J., Zaidi, M. F., Patel, M., Atluri, L. M., Gonzalez, N. A., & Alfonso, M. (2023) · Cureus · doi:10.7759/cureus.37335 · Cited by 5
Iliodromitis, K. E., Tzeis, S. E., Xintarakou, A., Pyrgakis, V. N., Zarifis, Ι., Patsilinakos, S. P., Draganigos, A., Triposkiadis, F. K., Hahalis, G. N., Karanasios, A., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.04.008 · Cited by 6
Pharmacological Therapy Optimization for Heart Failure: A Practical Guide for the Internist
Dimza, M., Kurup, V., Canha, C., Jimenez, A., Al‐Ani, M. A., Parker, A. M., Vilaro, J. R., Ahmed, M. M., & Aranda, J. M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.033 · Cited by 5
Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials
Linden, K., McQuillan, C., Brennan, P., & Menown, I. B. A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00962-1 · Cited by 5
Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz
Lauder, L., Ewen, S., Emrich, I. E., Böhm, M., & Mahfoud, F. (2019) · Herz · doi:10.1007/s00059-019-04846-6 · Cited by 6
Khandwalla, R. M., Birkeland, K. T., Heywood, J. T., Steinhubl, S. R., McCague, K., Fombu, E., Grant, D., Riebman, J. B., & Owens, R. L. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12514 · Cited by 7
Self-citationFerreira, J. P., Cleland, J. G. F., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., Police, D. A. L., Pitt, B., Greenberg, B., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01830-1 · Cited by 6
Gronda, E., Napoli, C., Iacoviello, M., Urbinati, S., Caldarola, P., Mannucci, E., Colivicchi, F., & Gabrielli, D. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab066 · Cited by 5
Imamura, T., Hori, M., & Kinugawa, K. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6713-20 · Cited by 5
Rezq, A., Saad, M. S., & Nozahi, M. E. (2021) · PubMed Central · Cited by 5
Intravenous Iron Therapy for Patients with Heart Failure: Expanding Body of Evidence
Adlbrecht, C. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12490 · Cited by 5
Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring
Bayés‐Genís, A., & Pascual-Figal, D. A. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad356 · Cited by 5
Rodriguez, R. W., & Kaluzna, S. D. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad061 · Cited by 4
Sadek, M. H. A., Aboul-Saud, M. I., Missiri, A. E., & Abdellatif, Y. (2025) · Journal of Cardiovascular Echography · doi:10.4103/jcecho.jcecho_58_24 · Cited by 4
Milhem, F. S., Almur, O., Hajjeh, O., Bdair, M., Dahmas, A. M., Haddad, K. B., Shubietah, A. R. M., Al-Said, O. S., Al-Braik, R., Abukhalil, M. M., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003592 · Cited by 6
Matsumoto, S., Nasu, T., Fujimoto, W., Kagiyama, N., Shiraishi, Y., Ishii, S., Ijichi, T., Nakazawa, G., Ikeda, T., Kanaoka, K., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.09.013 · Cited by 4
Evolving Decongestion Strategies in the Management of Acute Heart Failure
George, J., & Tang, W. H. W. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01125-y · Cited by 4
Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease
Madrini, V., Souza, P. V. R., Fernandes, F., Ianni, B. M., Martins, A. S., Luzuriaga, G. D. C. J., Fonseca, K. C. B., Ribeiro, O. N., da Cruz, A. B., de Oliveira, R. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.053 · Cited by 8
Meuwese, C. L., van Steenwijk, M. P. J., Møller, J. E., Melkert, J. A., Donker, D. W., & de Boer, R. A. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.12.006 · Cited by 5
Quadruple therapy in heart failure: Why, when, and in whom?
PARASKEVAIDIS, I. A., Tsougos, E., & Kourek, C. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103352 · Cited by 5
Treatment of Heart Failure with reduced Ejection Fraction in 2022: The Essential Pillars
Bonatto, M. G., Coiradas, A. D. O., & Moura, L. Z. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220003 · Cited by 2
Hlaváček, D., Haluzík, M., Mahrík, J., Popivnyak, G., Kasperová, B. J., & Ivák, P. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2511388 · Cited by 4
Blaj-Tunduc, I. P., Brisc, C., Brisc, M. C., Zaha, D. C., Bustea, C., Babeş, V. V., Sirca, T. B., Muste, F. A., & Babeş, E. E. (2025) · Medicina · doi:10.3390/medicina61081451 · Cited by 5
Meems, L. M. G., van Veldhuisen, D. J., & de Boer, R. A. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01453-7 · Cited by 5
Consenso de actuación básica durante el ingreso hospitalario por insuficiencia cardiaca aguda
Rodríguez, J. M. F., Casado, J., Formiga, F., Franco, Á. G., Arévalo‐Lorido, J. C., Beltrán, M., González, J., Llàcer, P., Manzano, L., Morales‐Rull, J. L., et al. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.01.002 · Cited by 5
A novel model of myocardial infarction based on atherosclerosis in mice
Wang, J., Shan, S., Lyu, A., Wan, Y., & Zhang, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.006 · Cited by 4
Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Abdelnabi, M. H., Saleh, Y., Almaghraby, A. M., Girgis, H., & Gerges, F. (2021) · Current Cardiology Reviews · doi:10.2174/1573403x17666210831142452 · Cited by 5
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.